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Abstract Evidence suggests hyperglycemia is associated
with worse outcomes in glioblastoma (GB). This study aims
to confirm the association between glycemia during radio-
therapy (RT) and temozolomide (TMZ) treatment and
overall survival (OS) in patients with newly diagnosed GB.
This retrospective study included GB patients treated with
RT and TMZ from 2004 to 2011, randomly divided into
independent derivation and validation datasets. Time-
weighted mean (TWM) glucose and dexamethasone dose
were collected from start of RT to 4 weeks after RT. Uni-
variate (UVA) and multivariable (MVA) analyses investi-
gated the association of TWM glucose and other prognostic
factors with overall survival (OS). In total, 393 patients with
median follow-up of 14 months were analyzed. In the
derivation set (n = 196) the median OS was 15 months and
median TWM glucose was 6.3 mmol/L. For patients with a
TWM glucose B6.3 and[6.3 mmol/L, median OS was 16
and 13 months, respectively (p = 0.03). On UVA, TWM
glucose, TWM dexamethasone, age, extent of surgery, and
performance status were associated with OS. On MVA,
TWM glucose remained an independent predictor of OS
(p = 0.03) along with TWM dexamethasone, age, and sur-
gery. The validation set (n = 197), with similar baseline
characteristics, confirmed that TWM glucose B6.3 mmol/L
was independently associated with longer OS (p = 0.005).
This study demonstrates and validates that glycemia is an
independent predictor for survival in GB patients treated
with RT and TMZ.
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Introduction
Glioblastoma (GB) is the most common malignant primary
brain tumor in adults. Despite aggressive surgical resection
and combined temozolomide chemotherapy and radiotherapy
(RT), even in younger patients with good performance status,
the median survival remains relatively poor at 14.6 months
[1]. Therefore, novel approaches are required to improve
outcomes for patients with this devastating diagnosis.
A number of factors have been identified to be prognostic
for survival in GB patients including age, performance sta-
tus, neurological function, neurocognitive function, extent of
surgical resection, MGMT promoter methylation and IDH1
mutation [2–5]. These factors are typically considered when
making recommendations regarding an individual’s initial
treatment.
There is growing evidence that blood glucose and
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development and growth, including GB [6–12].
Specifically for GB, it has been reported that altered
mechanisms of energy metabolism impact tumor growth
[13]. The Warburg effect has been suggested as the
mechanism for greater tumor dependence on glucose for
growth in GB cells in vitro [14]. Under this hypothesis a
high glucose environment may promote tumor growth and
progression. In addition, associated insulin resistance and
high circulating insulin may further promote tumor growth
via insulin like growth factor (IGF) signaling pathways
[15]. Studies suggest that patients with solid cancers, in-
cluding breast and colon cancer, have worse survival if
they also have pre-existing diabetes [16].
For patients with GB, two retrospective studies have
shown an association between higher blood glucose levels
and worse survival [17, 18]. However, these studies in-
cluded heterogeneous patient populations who received a
variety of treatments including various doses and schedules
of RT and inconsistent treatment with temozolomide fol-
lowing surgery. In addition, these studies did not account
for a major confounding factor, dexamethasone use, and
evaluated blood glucose levels at variable time points with
various approaches.
This study aimed to investigate the association between
glycemia and survival in GB patients treated with standard
of care six-week course of RT concurrently with temo-
zolomide following surgery, and was designed to quanti-
tatively account for major confounding factors including
dexamethasone dose and to incorporate both a derivation
and validation set.
Materials and methods
This was a single institution retrospective study with in-
dependent derivation and validation cohorts of patients
treated at a tertiary cancer centre for histologically-con-
firmed GB. Patients were treated between January 2004
and June 2011 with definitive RT to a total dose of 54 to
60 Gy in 30 daily weekday fractions of 1.8 to 2 Gy per day
using conformal techniques in combination with concur-
rent temozolomide 75 mg/m2 daily. This was generally
followed with adjuvant temozolomide 150–200 mg/m2.
Variability in clinical approaches to therapy was not ob-
served over the course of the study period. Patients were
excluded if they had no blood glucose documentation, re-
ceived other radiation doses or fractionation schedules or
received no concurrent temozolomide.
After receiving institutional research ethics approval, an
electronic chart review was completed to collect the fol-
lowing baseline patient and tumor characteristics: age at
treatment, body mass index (BMI), prior history of diabetes
and use of diabetic medication, Eastern Co-operative
Group (ECOG) performance status, and isocitrate dehy-
drogenase 1 (IDH-1) mutation status. The following treat-
ment factors were collected: extent of surgery, radiation
dose fractionation and temozolomide treatment details. At
our institution, random blood glucose levels were measured
routinely at the time of surgery, prior to RT, weekly during
the course of RT and monthly during adjuvant temozolo-
mide. Dexamethasone doses were also recorded at the time
of initial consultation, regularly during RT and in follow-
up after completion of RT. For each patient, time weighted
mean (TWM) values were calculated from start of RT to
4 weeks following completion of RT (week 10) for serial
blood glucose measurements (TWM glucose) and dexam-
ethasone doses The calculation of TWM values incorpo-
rates multiple measures between a pre-determined time
period (i.e. 10 weeks for this study) and accounts for the
time between each measure. This method helps account for
the effects of variability in these measures over the
10-week period. For dexamethasone, this approach helps
determine the most representative average dexamethasone
exposure over the 10 weeks, accounting for titration of
dose during this period to manage symptoms. For glucose
levels, this approach helps account for changes in glucose
level over the 10-week period and helps reduce the impact
of variability in glucose levels when they are taken ran-
domly as opposed to consistent fasting glucose readings.





where x = the proportion of days until either the next
measurement or the 28th day following RT and x = either
blood glucose measurements or dose of dexamethasone,
whichever is being calculated.
Statistical analysis
Study subjects were randomly divided into two subgroups,
the Derivation Set and the Validation Set, using Simple
Random Sampling in order to minimize any bias associated
with changes in practices and reflected outcomes over time.
Differences in baseline characteristics between the two sets
were assessed using linear regression for continuous
parametric variables, the Wilcoxon rank-sum test for
nonparametric continuous variables, and logistic regression
for dichotomous and categorical variables.
Survival time was calculated as the time between di-
agnosis of the tumor and the date of death; observations
were censored if the subject was alive at the date of last
contact. The effect of glycemia on overall survival in the
Derivation Set was assessed using a Cox proportional
hazards model. The Derivation Set was then divided into
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two groups based on the subjects’ TWM glucose, one
group with glucose less than or equal to the median, the
other with glucose greater than the median. Univariate Cox
regression was also used to evaluate the effects of other
variables on survival, and those with significant p-values
were then included in a multivariable model to determine
the independent association of glucose and overall survival.
This process was then repeated in the Validation Set, using
the same glucose cut-off as the Derivation Set. Kaplan–
Meier survival curves were generated for both sets, with
subjects divided by their TWM glucose. Statistical analysis
was performed using SAS version 9.3 for Windows (SAS




A total of 393 patients met eligibility criteria and were
included in the final analysis. The entire cohort had a mean
age of 54 years. Median follow up for the study population
was 14 months (1–104 months) and median survival was
15 months. The majority of patients (86 %) had a perfor-
mance status of ECOG 0–1. The majority of patients
(91 %) also received dexamethasone during treatment.
Only 9 % of patients had a prior diagnosis of diabetes
mellitus and mean BMI was 27.2 kg/m2. The mean number
of glucose readings per patient was 5 ± 2. The IDH-1
mutation status was confirmed for 127 (32 %) cases of
which 7 (6 %) were IDH-1 mutation positive.
Patients were divided randomly into a derivation set of
196 patients and a validation set of 197 patients. Baseline
characteristics of the derivation and validation set are
summarized in Table 1. The derivation and validation co-
horts were similar with regards to patient age, BMI, per-
formance status, extent of surgery and radiation dose
fractionation regimens. Fewer patients in the validation set
were on dexamethasone (88 vs. 95 %, p = 0.01). In the
derivation and validation sets, 5/73 (7 %) patients and 2/54
(4 %) patients had IDH-1 positive tumors respectively.
Derivation set
The derivation set included 196 patients with a median sur-
vival of 15 months. The relationship between TWM glucose
and survival was initially examined in deciles. A univariate
model revealed that the hazard ratio (HR) increased sig-
nificantly above the median TWM glucose of 6.3 mmol/L,
above the 5th decile (Fig. 1). Hence patients were divided
into two groups, above and below this median TWMglucose.
Themedian overall survival for patients with a TWMglucose
of B6.3 and[6.3 mmol/L was 16 and 13 months, respec-
tively (Fig. 2a). Patients with TWM glucose levels above
6.3 mmol/L were more likely to have pre-existing diabetes
(14 vs. 3 %, p = 0.01), and less likely to have received ad-
juvant monthly temozolomide following concurrent radiation
with temozolomide (67 vs. 91 %, p = 0.0001).
On univariate analysis (Table 2), factors that were as-
sociated with survival included TWM glucose, TWM
dexamethasone dose, age, ECOG performance status and
extent of surgery (biopsy vs partial/subtotal resection).
Although patients with higher glucose levels were more
likely to have pre-existing diabetes this factor was not as-
sociated with survival on UVA. On multivariable analysis,
TWM glucose remained an independent predictor of sur-
vival such that a TWM glucose of [6.3 mmol/L had a
hazard ratio for death of 1.47 (95 % CI: 1.05–2.06,
p = 0.03) (Table 3). Other factors that were independently
associated with survival on multivariable analysis included
TWM dexamethasone dose (HR 1.04, 95 % CI: 1.05–2.06,
p = 0.02), age (HR 1.02, 95 % CI: 1.01–1.04, p = 0.01)
and type of surgery (biopsy vs. partial/subtotal, HR 0.64,
95 % CI 0.43–0.95, p = 0.03).
When higher glucose cut-off values were explored,
survival was consistently worse for patients with glucose
values above the cut-off, and the adjusted hazard ratio grew
larger as higher cut-off values were used. In the derivation
set, the cut-off of 6.3 mmol/L yielded an adjusted HR of
1.47; 6.6 mmol/L yielded an adjusted HR of 1.53; 7.4 m-
mol/L yielded an adjusted HR of 1.58; and 8.2 mmol/L
yielded an adjusted HR of 1.88.
Validation set
The validation set included 197 patients. Median survival
for these patients was 16 months. The median TWM glu-
cose for the validation set was 6.0 mmol/L. Patients were
divided into two groups based on the glucose threshold
from the Derivation set. Median survival for patients with a
TWM glucose of B6.3 and [6.3 mmol/L was 20 and
13 months, respectively (Fig. 2b). Again, univariate ana-
lysis showed the following variables were associated with
survival: TWM glucose, time weighted mean dexametha-
sone dose, age, BMI, ECOG performance status and extent
of surgery (biopsy vs partial/subtotal resection). In this
validation cohort, time weighted mean glucose of greater
than or less than the previously defined median value of
6.3 mmol/L remained an independent prognostic factor for
survival on multivariable analysis. The hazard ratio for
death was 1.67 (95 % CI: 1.17–2.4, p = 0.005) for patients
with a time weighted mean glucose of[6.3 mmol/L when
compared with patients with B6.3 mmol/L (Table 3).
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Dexamethasone and glucose
The linear relationship between TWM glucose and TWM
dexamethasone was found to be weak, with a Spearman
rank-correlation coefficient of 0.20 (p\ 0.0001).
Discussion
Our study demonstrates an independent association between
higher blood glucose levels and survival in newly diagnosed
GB patients treated with concurrent RT and temozolomide.
Through independent derivation and validation cohorts, with
particular attention to confounding variables including
quantitative exposure to dexamethasone, we demonstrated
that patients with a TWM blood glucose[6.3 mmol/L have
significantly worse survival compared with those patients
whose TWM blood glucose was B6.3 mmol/L, with hazard
ratios of 1.47 in the derivation cohort and 1.67 in the
validation cohort. Other factors independently associated
with survival on multivariable analysis included TWM
dexamethasone dose (HR 1.04, 95 % CI: 1.05–2.06,
p = 0.02), age (HR 1.02, 95 % CI: 1.01–1.04, p = 0.01)
and type of surgery (biopsy vs. partial/subtotal, HR 0.64,
95 % CI 0.43–0.95, p = 0.03).
Higher dexamethasone requirements in patients may
reflect patients with larger post-operative tumour burden
and peritumoral edema, who are likely to have worse
prognosis. But higher dexamethasone dose intake is also
associated with increased insulin-resistance and this can
result in higher glucose and insulin levels. While the ana-
lysis in this patient cohort suggests a weak association
Table 1 Patient baseline
characteristics according to
derivation and validation set
Characteristics Set P-value
Derivation (n = 196) Validation (n = 197)
Age (average, years) 54 54 0.99
Female Gender, n (%) 71 (36 %) 71 (36 %) 0.97
BMI (kg/m2) 26.7 27.6 0.08
BMI C 25, n (%) 126 (64 %) 122 (62 %) 0.94
Pre-existing diabetes 17 (9 %) 19 (10 %) 0.74
Mean glucose (mmol/L) 7.4 7.0 0.30
ECOG performance status, n (%)
0–1 171 (87 %) 168 (85 %) 0.57
2–3 25 (13 %) 29 (15 %)
Proportion of patients on
Dexamethasone, n (%)
187 (95 %) 172 (88 %) 0.01
Mean TWM dexamethasone dose 4.5 4.0 0.03
Extent of surgery, n (%)
Subtotal 35 (18 %) 37 (19 %) 0.76
Partial 120 (61 %) 122 (62 %)
Biopsy 40 (20 %) 38 (19 %)
Unknown 1 (1 %) –
Radiation dose, n (%)
60/30 160 (82 %) 172 (87 %) 0.16
54/30 26 (13 %) 13 (7 %)
Other 10 (5 %) 12 (6 %)
Temozolomide n (%) 196 (100 %) 197 (100 %) –
Concurrent 41 (21 %) 36 (18 %) 0.51
Concurrent & adjuvant 155 (79 %) 161 (82 %)
Adjuvant cycle number 4 3 0.77
Metformin use 27 (14 %) 20 (10 %) 0.27
Hyperglycemia interventions 43 (22 %) 30 (15 %) 0.09
Salvage treatment, n (%) 114 (58 %) 119 (60 %) 0.65
Hospital admission, n (%) 86 (44 %) 82 (42 %) 0.65
Acute infection, n (%) 44 (22 %) 53 (27 %) 0.31
BMI body mass index, ECOG eastern cooperative oncology group, TWM time weighted mean
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between dexamethasone and glucose in this clinical setting,
it remains difficult to completely separate the impact of
higher dexamethasone dose on glycemia and outcomes,
given the known underlying physiological effects of cor-
ticosteroids on host glucose metabolism.
In our study, clinically meaningful differences in sur-
vival were observed with glucose levels above a glycemic
threshold of 6.3 mmol/L, which is within the clinically
accepted euglycemic range for random glucose. This low
glycemic threshold has been confirmed internally in our
Validation Set and is also consistent with the results of a
study published in the pre-temozolomide era by Derr et al.
[18]. This study divided glioblastoma patients into quar-
tiles on the basis of TWM glucose taken from RT until last
follow up date. It was reported that survival was poorer in
patients in the higher quartile groups. The median TWM
glucose in this study was 6.1 mmol/L. For patients with a
TWM glucose of 6.1–7.6 mmol/L and[7.6 mmol/L me-


































Fig. 1 Hazard Ratio according to time weightedmean glucose decile as
compared with first decile, in the derivation set. Dot shows hazard ratio
and error bars represents 95 % confidence interval. Deciles are divided
as follows: 4.1–\5.1 mmol/L, B5.1–\5.4 mmol/L, B5.4–\5.7 mmol/
L,B5.9–\6.3 mmol/L,B6.3–\6.6 mmol/L,B6.6–\7.4 mmol/L,B7.4–































baFig. 2 Kaplan Meier survival
curves for the derivation set
(a) and validation set
(b) divided by time weighted
glucose B6.3 and[6.3 mmol/L.
Derivation set adjusted p value
for trend = 0.03, validation set
adjusted p-value for
trend = 0.005
Table 2 Univariate association
between patient characteristics
and survival in derivation set
Characteristic HR 95 % CI P-value
Median TWM glucose
B6.3 mmol/L Reference
[6.3 mmol/L 1.59 (1.15,2.19) 0.005
Mean TWM dexamethasone dose, per mg 1.05 (1.02,1.08) 0.0005
Age, per year 1.02 (1.003,1.04) 0.02
BMI, kg/m2 1.00 (0.97,1.04) 0.76
Sex, female versus male 1.25 (0.90,1.75) 0.19
ECOG
0 or 1 Reference
2 or 3 1.88 (1.17,3.01) 0.009
Pre-existing Diabetes, no versus yes 1.50 (0.89,2.53) 0.13
Metformin, no versus yes 1.02 (0.65,1.61) 0.92
Surgery, biopsy versus partial/subtotal 0.57 (0.39,0.84) 0.004
BMI body mass index, ECOG eastern cooperative oncology group, TWM time weighted mean
J Neurooncol (2015) 124:119–126 123
123
was shorter than for patients with a TWM glucose of
\5.2 mmol/L and 5.2–6.1 mmol/L where median survival
was 14.5 and 11.6 months, respectively. In our study, the
difference in median survival for patients above and below
our glycemic threshold of 6.3 mmol/L was 3 months in the
derivation set and 7 months in the validation set. These
results are consistent with published data where the dif-
ference in survival between those with lower versus higher
blood glucose levels ranged from 4.9 to 6 months [17, 18].
This difference in survival is clinically meaningful for
patients with GB as their median survival is relatively
short at approximately 14.6 months if they have good
performance status and are treated with high dose RT and
temozolomide [1].
In current practice, glycemic interventions have generally
not been prioritized in patients undergoing treatment for GB.
Glycemic interventions are often deferred until patients’ glu-
cose levels are well beyond the renal threshold—i.e. blood
glucose levels[12 mmol/L. The consistent finding of im-
proved survival associatedwith lowerbloodglucose levels and
large survival differences in our study and previously pub-
lished literature, provides compelling evidence to motivate
investigation of intensive glycemic intervention with a lower
target glucose range to improve survival in patients with GB.
Several mechanisms may contribute to the association
between glycemia and GB survival including role of glucose
as a substrate and associated insulin levels. Preclinical
studies have demonstrated the Warburg effect, preferential
anaerobic metabolism through glycolysis even in the pres-
ence of sufficient oxygen, in GB cells and xenograft models
[19–21]. As glycolysis requires more glucose to produce the
same amount of energy, it is postulated that the preferential
glycolytic metabolism of GB tumors results in greater glu-
cose dependence. Dependence of GB cell lines on glucose
has been demonstrated in preclinical experiments in which
withdrawal of glucose resulted in extensive apoptosis in GB
cell lines but not in normal human astrocytes [14]. Epi-
demiologic studies have reported that breast cancer, col-
orectal cancer and high grade glioma patients with type 2
diabetes have worse outcomes compared to their non-
diabetic counterparts [12, 16]. In addition to hyperglycemia,
patients with type 2 diabetes have hyperinsulinemia as a
result of insulin-resistance. Higher circulating insulin levels
may facilitate tumour growth through stimulation of the in-
sulin-like growth factor (IGF) signalling pathways as insulin
ligands have demonstrated high affinity to IGF-1 receptors
[15, 22–24]. Glioblastoma cell lines have been shown to
express IGF-1 receptors and laboratory studies have
demonstrated that stimulation of the IGF-1 receptor results in
GB tumor proliferation and migration [25].
Therefore, interventions that target lowering glucose
levels as well as lowering insulin levels may improve
Table 3 Multivariable
association between patient
characteristics and survival in
derivation and validation sets




[6.3 mmol/L 1.47 (1.05,2.06) 0.03
Mean TWM dexamethasone dose, per mg 1.04 (1.01,1.07) 0.02
ECOG performance status
0 or 1 Reference
2 or 3 1.45 (0.83,2.54) 0.19
Age, per year 1.02 (1.01,1.04) 0.01
BMI, kg/m2 0.99 (0.95,1.03) 0.57




[6.3 mmol/L 1.67 (1.17,2.40) 0.005
Mean TWM dexamethasone dose, per mg 1.08 (1.04,1.11) \0.0001
ECOG performance status
0 or 1 Reference
2 or 3 1.55 (0.91,2.65) 0.11
Age, per year 1.03 (1.01,1.05) 0.01
BMI, kg/m2 1.04 (1.01,1.08) 0.02
Surgery, biopsy versus partial/subtotal 1.04 (0.64,1.67) 0.88
BMI body mass index, ECOG eastern cooperative oncology group, TWM time weighted mean
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outcomes of patients with GB. Recent studies have evaluated
the potential for ketogenic diet approaches to reduce glucose
levels. Strict administration of a ketogenic diet has been able
to achieve blood glucose levels as low as 50–65 mg/dl
(2.8–3.6 mmol/L), a range where induction of ketogenesis
results. Laboratory experiments in animal models have sug-
gested that a ketogenic diet and 2-deoxy-D-glucose adminis-
tration impairs astrocytoma growth [26] and that this fasting
state may sensitize glioma cells to RT and temozolomide
[27]. To date, clinical data of ketogenic diets in GB patients
are limited to a small retrospective review and case studies
[28, 29]. Similarly, there have been small feasibility studies
reported in metastatic cancer patients [30, 31]. Reports of
tolerability of ketogenic diet in cancer patients are variable
and larger trials for further assessment are warranted. In the
GB patient population, alternative approaches for reducing
blood glucose levels, such as oral diabetic agentsmay bemore
feasible than dietary restriction. We have planned a pilot
study to assess the feasibility of early glycemic intervention
with lower target glucose levels (4–7 mmol/L) in GB patients
using diabetic agents including metformin, an agent that
would potentially reduce both glucose and insulin levels.
Due to the retrospective nature of this study with inclu-
sion of patients treated prior to the era of standard IDH-1
mutation testing; only 32 % of tumors had confirmed IDH-1
mutation results. Of the tumors that were tested only 6 %
were found to harbor the IDH-1 mutation. The mechanism
of through which IDH-1 mutation effect tumor outcomes is
not well understood. One of the proposed mechanisms of
relevance to our study is that GBM cells harboring the IDH
mutation have impaired glucose oxidation leading to re-
duced production of energy and other substrates used for
biosynthesis and resulting in slower growth rates [32, 33].
Based on this proposed mechanism, higher glucose exposure
may not drive metabolism in tumors with IDH-1 mutations.
However considering the small proportion of IDH-1 mutated
tumors in our cohort, only 6 % of all evaluated tumors, the
IDH mutations status of cases included in this study are
unlikely to confound our findings.
As this is a retrospective study that included patients
treated over a long time period, limitations of the study
include the lack of O6-methylguanine–DNA methyltrans-
ferase (MGMT) methylation status and IDH-1 mutation
status for only a portion of tumours. As the majority of our
patients were treated prior to the era of recognizing pseu-
doprogression, we were unable to reliably assess the impact
of glucose on local tumour progression, as patients re-
ceived further treatment for radiological ‘progression’
shortly after completing concurrent temozolomide and RT.
For these cases, we could not determine whether subse-
quent radiological improvement represented response to
further treatment or resolution of pseudoprogression over
time. A retrospective study has shown that patients with
low-grade glioma who had persistent outpatient hyper-
glycemia (serum glucose[10 mmol/L on C3 occasions)
had higher rates of tumor recurrence and lower survival
[34]. Investigation of a more recent cohort of patients or
prospective investigation of patients treated with concur-
rent radiation and temozolomide would help confirm the
association between glycemia and tumor progression in
patients with GB.
Conclusion
Our findings demonstrate that glycemia is an independent
predictor for survival in GB patients treated with RT and
TMZ. This is independent of other known prognostic fac-
tors including age, extent of surgery, and dexamethasone
requirements. In this study, incrementally lower glucose
levels, even within the normal glycemic range, were as-
sociated with better survival. This motivates prospective
clinical studies to investigate the effect of intense glycemic
intervention during concurrent and adjuvant radiation and
temozolomide therapy to maintain lower glucose levels in
patients with glioblastoma.
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